



Positive results for Intercell's Japanese Encephalitis virus vaccine in pivotal clinical trial – Phase III meets primary endpoint

- » First results for Intercell's Japanese Encephalitis virus vaccine in the pivotal immunogenicity clinical trial are positive
- » In a preliminary statistical analysis, the primary endpoint of non-inferiority of Intercell's investigational vaccine compared with JE-VAX® was met
- » With these results, the filing process with the United States Food and Drug Administration (FDA) will start shortly to prepare for the market launch in the United States expected in 2007

Vienna (Austria), May 31, 2006 – Intercell AG (VSE, "ICLL") announced today that a first analysis of the pivotal immunogenicity phase III clinical data of its investigational Japanese Encephalitis virus (JEV) vaccine showed positive results and met its primary endpoint. The primary endpoint in this clinical trial comprised both the amount of antibodies in the blood (expressed as geometric mean titer or GMT) and the percentage of subjects reaching protective antibody titers (known as the seroconversion rate).

The clinical trial was designed to compare the immunogenicity of Intercell's investigational vaccine with the mouse brain derived JE-VAX® (distributed by Sanofi Pasteur SA, produced by Biken) in a multicenter, multinational, observer-blinded, randomized controlled trial. The pivotal immunogenicity phase III clinical trial was conducted at study sites in the United States, Austria, and Germany and included 868 randomized subjects. The pivotal Phase III clinical trial program is designed to meet the regulatory requirements of Intercell's JEV vaccine in the United States, Europe and Australia. The first market launch is expected to take place in the United States in 2007, if the company obtains timely approvals from the regulatory authorities.

The full phase III clinical trial program consists of several additional clinical trials including a pivotal safety trial, a single shot trial and a co-vaccination trial for travelers, which are all expected to be completed by early 2007. To date, more than 4,800 of the approximately 5,370 trial participants have been enrolled and vaccinated in these clinical trials. Preparations for the submission of a BLA (Biologics License Application) to the FDA have commenced.

In January 2006, an independent data and safety monitoring board concluded that it observed no safety concerns in its first evaluation. In addition, Intercell's JEV vaccine was granted orphan drug status by the European Commission, resulting in ten years of market exclusivity in the European Union upon product registration.

"Based on the positive immunogenicity and safety profile observed so far, we believe that our innovative product will replace the mouse-brain derived products currently available on the market and that we will be able to expand the market for this traveler vaccine



significantly. We are very proud that we are one of the few companies in the rapidly growing vaccine market that is running a globally successful phase III clinical program, states Intercell's Chief Executive Officer, Gerd Zettlmeissl.

Full clinical trial data will be presented at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH), which is scheduled to take place from November 12 to 16, 2006, in Atlanta.

About Intercell's investigational JEV vaccine

Intercell's novel investigational JEV vaccine is a purified, inactivated vaccine for active immunization of adults against the Japanese Encephalitis virus. With over three billion people living in endemic areas, Japanese Encephalitis, a mosquito-borne flaviviral infection, is the leading cause of childhood encephalitis and viral encephalitis in Asia.

In a former phase II head-to-head comparison with JE-VAX®, the only JEV vaccine licensed in the United States, Intercell's investigational vaccine was shown to be:

- » Less reactogenic – both in frequency and intensity
- » More potent – higher antibody levels at all doses studied one month after the immunizations
- » More convenient – 2 doses versus 3 doses and liquid versus freeze-dried format
- » More persistent – higher persistence of antibodies two years after primary immunization

Intercell's JEV vaccine, manufactured in the Company's propriety manufacturing facility in Scotland, is novel as it is based on tissue culture rather than live organisms and does not contain any stabilizers or preservatives in its formulation.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unmet medical need. The Company develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Sanofi Pasteur S.A., Merck & Co., Inc., SciGen Ltd., the Statens Serum Institut and Kirin Brewery Co., Ltd.. The Company has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in phase III, a vaccine product candidate for Hepatitis C in phase II, partnered vaccine candidates for tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com



Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.